Podcasts

Episode 65 | ALK TKI Sequencing in the Australian Landscape

In this episode, we welcome A/Prof Tim Clay, Prof Ben Solomon and A/Prof Malinda Itchins

Episode Summary

In this episode of TOGA’s Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.

This episode is sponsored by Pfizer.

Speakers

A/Prof Tim Clay, Medical Oncologist, St John of God Subiaco Hospital
Prof Ben Solomon, Medical Oncologist at the Peter MacCallum Cancer Centre
A/Prof Malinda Itchins, Medical Oncologist, Royal North Shore Hospital and Chris O’Brien Lifehouse

Timestamps

(00:00) Welcome and Acknowledgement

(00:43) Meet the Expert Guests

(01:40) ALK History and Breakthroughs

(03:48) Who Gets ALK Lung Cancer

(04:57) Workup and Staging Essentials

(05:54) Patterns of Spread and Clots

(07:24) Second Generation TKIs Standard

(09:03) Long Term Toxicities

(11:07) Progression Assessment and LAT

(12:50) Lorlatinib After Progression

(15:46) Lorlatinib First Line Crown Data

(17:11) Choosing and Dosing Lorlatinib

(20:55) Managing Lorlatinib Side Effects

(22:29) Predicting Response and Follow Up

(29:30) Next Generation Inhibitors NAL

(32:04) Early Stage and Adjuvant TKIs

(36:32) Beyond TKIs Chemo and ADCs

(39:30) Patient Support and Closing

Play Episode 65 | ALK TKI Sequencing in the Australian Landscape

More Podcasts

75 – The Evolving Landscape of ROS1-positive NSCLC

Podcasts
September 4, 2026

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,

74 – Prof Zarnie Lwin OAM: Mentorship, Research, and the Future of Lung Cancer Treatment

Podcasts
August 28, 2026

Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.

73 – Smoking Stigma and Lung Cancer Care in the Screening Era

Podcasts
August 14, 2026

A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.

72 – Dr Jazmin Eckhaus: Robotic Innovations and Ethics in Thoracic Surgery

Podcasts
July 31, 2026

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.

71 – Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

Podcasts
June 26, 2026

Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.

70 – Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

Podcasts
June 19, 2026

Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.